{
  "id": 20254120,
  "title": "Samsung Biologics Rights Offering Draws 11.44 Trillion Won in Subscription Deposits",
  "url": "https://urgent.news/2026/11/16/samsung-biologics-rights-offering-draws-11-44-trillion-won-in",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-16T03:56:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=281364"
  },
  "original_language": "en",
  "account": null,
  "summary": "Samsung Biologics' rights offering has attracted impressive market demand, with more than 11 trillion won in subscription deposits. This represents a subscription rate of 13,562.32%, with a competition ratio of 135.6 to 1. The offering, which was conducted from November 12 to 13, saw applications for a total of 9,745,071 shares, and investors needed to deposit approximately 160 million won in subscription funds to receive one share. The total amount to be raised from the rights offering is 2.67 trillion won, with 2,270,000 new shares scheduled to be issued. The acquisition of PolyPeptide Group, a global peptide CDMO, is planned for completion using the proceeds from this rights offering.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}